Business Wire

AZ-AXWAY

23.8.2022 08:02:12 CEST | Business Wire | Press release

Share
Axway Named a Leader in Latest API Management Solutions Report

Axway (Euronext: AXW.PA), a leading provider of API management and integration software, is proud to announce that it has been positioned as a Leader in The Forrester Wave™: API Management Solutions, Q3 2022, published on August 22, 2022¹.

“We are honored that our customers could share their positive experience with Axway,” says Vince Padua, Chief Technology and Innovation Officer at Axway. “We feel it’s validation of our open platform vision and our focus on helping businesses extend their APIs further with the right strategy.”

Axway was one of 15 select companies that Forrester invited to participate in its 2022 Forrester Wave™ evaluation, The Forrester Wave™: API Management Solutions, Q3 2022. In this evaluation of its Amplify API Management Platform , Axway earned the highest scores possible in 12 evaluation criteria, including advanced policy and tooling, analytics and reporting, product vision, and market approach.

The report notes: “API design and publishing is strong, with support for GraphQL, multiple asynchronous protocols, AsyncAPI, and proxy of numerous backend protocols with REST. It has distinctive support for API discovery, consumer onboarding, and analytics collection from third-party gateways paired with good dashboards and reporting.”

According to the report, “Reference customers praise Catalysts, with one calling it an ‘absolute must-have’ service. Customers also praise Axway’s focus on customer success and the product’s scalability.” ¹

“The Amplify platform lets you discover, use, and govern APIs across multiple gateways, vendors, and environments, simplifying adoption and use of APIs. But providing an industry-leading API management solution isn’t enough,” adds Padua. “Just as essential is accompanying our customers in designing an API management strategy that will drive the best results from a company’s investment.”

With Amplify – and with expert guidance from Axway – leading research-driven pharma company Boehringer Ingelheim is generating value through API-powered digital solutions in the cloud.

“Our partnership with Axway means we no longer have to build, manage and maintain thousands of separate interfaces with no flexibility or reusability. We’ve already implemented key initiatives within our human pharmaceuticals and animal health business units to reimagine key business capabilities as API products. These API products are accelerating our digital transformation journey,” said Jon Nyholt, Head of IT EDS Architecture.

“We’re continuing to work closely with Axway Catalysts to refine our approach to API management — and we’re confident that we are building capabilities that will enable us to leap ahead of the pack. We are realizing with the help of Axway Catalysts that we need to focus on adoption efforts beyond technology,” said Siddharth Dixit, head of IT EDS Data and application integration.

Commerzbank is a leading German private and corporate bank with international presence. Powered by Amplify, they are now able to create new business models enabling innovative fintech partnerships.

“Axway has been a great support to us – not only in running an API platform but also in increasing our visibility for potential partners in the digital market,” says Christoph Berentzen, Head of API & Open Banking at Commerzbank.

Click here to view the complete Forrester Wave™ report.

¹The Forrester Wave™: API Management Solutions, Q3 2022, Forrester Research, Inc., August 22, 2022

About Axway

Axway enables enterprises to securely open everything by integrating and moving data across a complex world of new and old technologies. Axway’s API-driven B2B integration and MFT software, refined over 20 years, complements Axway Amplify, an open API management platform that makes APIs easier to discover and reuse across multiple teams, vendors, and cloud environments. Axway has helped over 11,000 businesses unlock the full value of their existing digital ecosystems to create brilliant experiences, innovate new services, and reach new markets. Learn more at axway.com

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision16.9.2026 14:23:00 CEST | Press release

The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916231950/en/ Outdoor relaxation area at Jayasom Wellness Resort AMAALA, where serene design and sea-facing spaces create a setting for rest and renewal. Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal. “As we launch the first Jayasom globally, w

Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth16.9.2026 14:01:00 CEST | Press release

AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trialsRubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind. This press release features multimedia. View

NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence16.9.2026 14:00:00 CEST | Press release

New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond. “NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infr

Unique Australian Clay: Multi Minerals Australia’s Non-antibiotic Solution for Poultry Production16.9.2026 13:44:00 CEST | Press release

Multi Minerals Australia, a leading mining company, announced a one-of-a-kind formulation of Australian clays which has proven it can reshape the global poultry feed economic landscape. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260916711777/en/ Unique, non-antibiotic clay stockfeed component and production enhancer from Multi Minerals Australia. Sourced from its one-of-a-kind geological deposit. Proven results. Worldwide distribution. Potential applications and lower cost benefits to a range of commercial animal production, particularly poultry. Expressions of interest sought. Numerous scientific, clinical, and commercial producer validations have demonstrated the product’s significant benefits; including the reduction of feed costs; improvements in: growth; meat yield; feed conversion; resistance to heat stress; eggshell quality and production: reduced inflammation and mortality in layer and broiler production. It has

Compass Pathways to Participate in TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 202616.9.2026 12:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026 and will participate in a fireside chat at 1:00pm ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/fAK4ioHxQNLX5A2utMmqiy/2vkuNBQpn65oayAPDgU4rZ A replay of the webcast will be accessible for 30 days following each event at the “Events” page of the Investors section of the Compass website. About Compass Pathways We believe mental health patients deserve the possibility of a better future. Compass Pathways plc (Nasdaq: CMPS) is a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care. Our initial focus is developing COMP360 psilocybin, a proprietary, investigational, synthetic psilocybin treat

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye